CN104507918A - 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法 - Google Patents

用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法 Download PDF

Info

Publication number
CN104507918A
CN104507918A CN201380034589.0A CN201380034589A CN104507918A CN 104507918 A CN104507918 A CN 104507918A CN 201380034589 A CN201380034589 A CN 201380034589A CN 104507918 A CN104507918 A CN 104507918A
Authority
CN
China
Prior art keywords
mdt
crystalline form
pattern
anhydride
diffraction peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380034589.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·O·库克
E·R·雷诺兹
B·沙库诺威
S·I·泽戈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdose Therapeutx Inc
Original Assignee
Microdose Therapeutx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microdose Therapeutx Inc filed Critical Microdose Therapeutx Inc
Publication of CN104507918A publication Critical patent/CN104507918A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380034589.0A 2012-06-29 2013-06-28 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法 Pending CN104507918A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
US61/666,258 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (1)

Publication Number Publication Date
CN104507918A true CN104507918A (zh) 2015-04-08

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380034589.0A Pending CN104507918A (zh) 2012-06-29 2013-06-28 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法

Country Status (17)

Country Link
US (2) US9040569B2 (enExample)
EP (1) EP2867216A4 (enExample)
JP (1) JP2015524391A (enExample)
KR (1) KR20150037946A (enExample)
CN (1) CN104507918A (enExample)
AU (1) AU2013282286A1 (enExample)
BR (1) BR112014032290A2 (enExample)
CA (1) CA2877941A1 (enExample)
EA (1) EA201590124A1 (enExample)
HK (2) HK1210163A1 (enExample)
IL (1) IL236476A0 (enExample)
IN (1) IN2014DN10680A (enExample)
MX (1) MX2014015340A (enExample)
NZ (1) NZ628880A (enExample)
TW (1) TWI516283B (enExample)
WO (1) WO2014005098A2 (enExample)
ZA (1) ZA201409073B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590124A1 (ru) 2012-06-29 2015-06-30 Майкродоуз Терапьютикс, Инк. Композиции и способы лечения или предупреждения пневмовирусной инфекции и связанных заболеваний
JP2017537958A (ja) * 2014-12-18 2017-12-21 メトリオファーム アーゲー ５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
KR20180105129A (ko) * 2015-11-30 2018-09-27 노부스 테라퓨틱스, 인크. 이과학적 예방 및 치료를 위한 조성물 및 방법
US10238821B2 (en) 2016-10-11 2019-03-26 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
US20200085741A1 (en) * 2018-09-14 2020-03-19 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289248A (zh) * 1998-01-29 2001-03-28 维洛药品公司 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法
US20050288345A1 (en) * 2002-08-09 2005-12-29 Rys David J Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
US8202896B2 (en) 2002-08-09 2012-06-19 Microdose Therapeutx, Inc. Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EA201590124A1 (ru) 2012-06-29 2015-06-30 Майкродоуз Терапьютикс, Инк. Композиции и способы лечения или предупреждения пневмовирусной инфекции и связанных заболеваний

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289248A (zh) * 1998-01-29 2001-03-28 维洛药品公司 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法
US20050288345A1 (en) * 2002-08-09 2005-12-29 Rys David J Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRAIG J. MORTON,等: "Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay", 《VIROLOGY》 *
JANET L. DOUGLAS,等: "Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein", 《JOURNAL OF VIROLOGY》 *
PHILIP R. WYDE,等: "Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol", 《ANTIVIRAL RESEARCH》 *
PHILIP R. WYDE,等: "Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro", 《ANTIVIRAL RESEARCH》 *

Also Published As

Publication number Publication date
NZ628880A (en) 2016-08-26
HK1210163A1 (en) 2016-04-15
BR112014032290A2 (pt) 2017-06-27
EP2867216A2 (en) 2015-05-06
US9504672B2 (en) 2016-11-29
US9040569B2 (en) 2015-05-26
EA201590124A1 (ru) 2015-06-30
TW201416093A (zh) 2014-05-01
US20140005239A1 (en) 2014-01-02
CA2877941A1 (en) 2014-01-03
ZA201409073B (en) 2016-08-31
KR20150037946A (ko) 2015-04-08
US20150209328A1 (en) 2015-07-30
IL236476A0 (en) 2015-02-26
TWI516283B (zh) 2016-01-11
AU2013282286A1 (en) 2015-01-22
WO2014005098A2 (en) 2014-01-03
MX2014015340A (es) 2015-03-05
IN2014DN10680A (enExample) 2015-08-28
WO2014005098A3 (en) 2014-02-27
JP2015524391A (ja) 2015-08-24
EP2867216A4 (en) 2015-12-09
HK1203956A1 (en) 2015-11-06

Similar Documents

Publication Publication Date Title
ES2741444T3 (es) Inhibidores de la replicación de virus de la gripe
WO2021206877A1 (en) Inhibitors of norovirus and coronavirus replication
TWI516283B (zh) 用於治療或預防肺病毒感染與相關疾病之組合物及方法
JP5665538B2 (ja) （１ｓ，２ｓ，３ｓ，４ｒ）−３−［（１ｓ）−１−アセチルアミノ−２−エチル−ブチル］−４−グアニジノ−２−ヒドロキシ−シクロペンチル−１−カルボン酸水和物及びその使用
CN101715343A (zh) 流感治疗药
BR112017005104B1 (pt) Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos
AU2016225000B2 (en) Inhibition of Olig2 activity
EP1996552A1 (en) Montelukast amantadine salt
CN102924302A (zh) 注射级盐酸氨溴索及其吸入用溶液
ES2899367T3 (es) Forma amorfa de trifenatato de vilanterol y procedimientos para su preparación
CN118103351A (zh) 冠状病毒抑制剂
CN102351895A (zh) 甲磷丙泊酚二钠水合物及其制备方法和用途
CN103833712B (zh) 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
CN108904489A (zh) 5,7-甲氧基3,4’羟基黄酮的抗呼吸道炎症性疾病的用途
JP6857617B2 (ja) インフルエンザウイルスの複製の阻害剤
CN115666510A (zh) 用于治疗或预防病毒感染的氯法齐明组合物和方法
WO2021052441A1 (zh) 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
CN113116899B (zh) 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
RU2821102C2 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
BRPI0615064A2 (pt) combinação de compostos que pode ser usada no tratamento de doenças respiratórias, especialmente, doença pulmonar obstrutiva crÈnica (dpoc) e asma
WO2019169112A1 (en) Inhibition of olig2 activity
EA050044B1 (ru) Твердые формы 2-(имидазол-4-ил)этанамида пентандиовой-1,5 кислоты
HK40084723B (en) Inhalation formulations of 1’-cyano substituted carbanucleoside analogs
BR112020001123B1 (pt) Formas cristalinas inovadoras de trifenatato de vilanterol e processos para sua preparação
PT110896B (pt) Forma amorfa de trifenatato de vilanterol e processos para a preparação da mesma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203956

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150408

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203956

Country of ref document: HK